Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LifeWatch ditches public offering bid:

This article was originally published in Clinica

Executive Summary

Cardiac monitoring company LifeWatch has cancelled its proposed IPO of around $86.3m worth of common stock. In a registration statement to the US Securities and Exchange Commission, the Rosemont, Illinois-based firm said that its board of directors had decided that "pursuing the initial public offering at this time is not in the best interests of the company". The IPO, which was originally filed in December 2006, was expected to provide funding to repay outstanding debt to LifeWatch's parent company, Swiss healthcare technology and solutions provider CardGuard. LifeWatch was also planning to use the proceeds to purchase, launch and market CardGuard's LifeStar ACT cardiac monitoring device and to support the relocation of its production facilities to a new site.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel